According to a Monday update with Sebi, Chemplast Sanmar and Tatva Chintan Pharma Chem acquired Sebi’s findings on July 2 and June 30, respectively. Any firm planning to conduct a public offering, such as an initial public offering (IPO), a follow-on public offering (FPO), or a rights issue must adhere to Sebi’s guidelines.
According to the draught papers, Chemplast Sanmar’s Rs 3,500 crore IPO includes a Rs 1,500 crore fresh issue of equity shares and a Rs 2,000 crore offer for sale. Sanmar Holdings Ltd and Sanmar Engineering Services Ltd are selling shares worth Rs 1,850 crore and Rs 150 crore, respectively, in the offer for sale.
About Chemplast Sanmar
Chemplast Sanmar is a prominent specialised chemicals company that specialises in speciality paste PVC (polyvinyl chloride) resin and bespoke manufacturing of raw ingredients and intermediates for the pharmaceutical, agrochemical, and fine chemicals industries. The net proceeds would be used to pay for the early redemption of the company’s non-convertible debentures (NCDs) to the tune of Rs 1,238.25 crore. The money will also be put to good use in the company.
About Tatva Chintan Pharma Chem
According to the draft red herring prospectus, Tatva Chintan Pharma Chem’s IPO consists of a fresh issue of equity shares worth Rs 225 crore and an offer of sale by current founders and shareholders for Rs 225 crore .The proceeds from the new offer will be utilised to pay capital expenditures for the company’s Dahej manufacturing facility, as well as upgrades to its R&D facility in Vadodara and other general business reasons.
Source; Economic times
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.